Infants born to mothers with asthma have more often bronchiolitis[@R1] and croup[@R2] but the effect of asthma management during pregnancy on these outcomes is unknown. We have conducted a double-blind randomised controlled trial and showed that the frequency of asthma exacerbations during pregnancy is reduced by ∼50% when treatments are guided by a management algorithm based on measurements of the fraction of exhaled nitric oxide (FeNO group) as compared to clinical symptoms (clinical group).[@R3] Here we report the effects of this optimised asthma management strategy during pregnancy on respiratory outcomes in infancy.

Subjects and methods {#s1}
====================

Of the 220 women who completed the clinical trial 79% (n=174) consented in writing to participate in the follow-up birth cohort study that was approved by the Hunter New England Health and University of Newcastle Human Research Ethics Committees. An examination of the infant and interview of the primary carer was conducted by the investigator (JM) who was blinded with respect to management group and pregnancy outcomes. A questionnaire was completed by the parent,[@R4] which contained a question on bronchiolitis and croup ('Has your child ever had the following conditions:' 'bronchiolitis'/'croup' 'Never'; 'Once'; 'More than once').

Logistic regressions were performed using STATA V.11. Any predictor variable with p\<0.1 on simple regression is shown in [table 1](#THORAXJNL2013203388TB1){ref-type="table"} and was included in a multiple regression model with stepwise removal for best fit. Predictor variables were tested for colinearity using STATA\'s variance inflation factors post estimation.

###### 

Relative risk of recurrent episodes of bronchiolitis or croup at 12 months of age in infants born to mothers from the clinical versus FeNO group employing regression analyses

  Bronchiolitis (multiple versus one or none episode)                                                                                        
  ----------------------------------------------------- ---------------- --------------- --------------------- ------- --------------------- -------
  Clinical vs FeNO group                                10/61 (16.4%)    1/67 (1.5%)     0.08 (0.01 to 0.62)   0.016   0.08 (0.01 to 0.66)   0.019
  Female vs male                                        35/61 (57.4%)    35/67 (52.3%)   1.02 (0.29 to 3.54)   0.975                         
  Gestational age (weeks)                               38.3 (2.7)†      38.9 (2.2)†     0.81 (0.67 to 0.97)   0.021   0.81 (0.67 to 0.99)   0.043
  Mother LABA during pregnancy                          12 /61 (19.7%)   28/67 (41.8%)   1.95 (0.56 to 6.82)   0.295                         
  Mother exacerbated during pregnancy                   30/61 (49.2%)    20/67 (29.9%)   3.01 (0.57 to 7.35)   0.093                         
  Mother Caesarean section                              19/58 (32.8%)    18/64 (28.1%)   0.85 (0.21 to 3.40)   0.817                         

  Croup (multiple versus one or none episode)                                                                                         
  --------------------------------------------- --------------- --------------- ---------------------- ------- ---------------------- -------
  Clinical vs FENO group                        7/62 (11.3%)    1/67 (1.5%)     0.12 (0.01 to 0.99)    0.050   0.15 (0.02 to 1.33)    0.089
  Female vs male                                36/62 (58.1%)   36/67 (53.7%)   1.38 (0.31 to 6.03)    0.672                          
  Gestational age (weeks)                       38.1 (3.0)†     39.0 (2.2)†     0.87 (0.71 to 1.05)    0.154                          
  Mother LABA during pregnancy                  13/62 (21.0%)   28/67 (41.8%)   0.18 (0 to 1.21)       0.084                          
  Mother exacerbated during pregnancy           31/62 (48.1%)   19/67 (28.4%)   5.25 (1.02 to 27.14)   0.048   3.88 (0.73 to 20.71)   0.113
  Mother caesarean section                      20/59 (33.9%)   18/64 (28.1%)   2.38 (0.56 to 10.08)   0.238                          

  Bronchiolitis or croup combined (multiple versus one or none episode)                                                                                        
  ----------------------------------------------------------------------- --------------- --------------- ---------------------- ------- --------------------- -------
  Clinical vs FENO group                                                  16/61 (26.2%)   2/66 (3.0%)     0.09 (0.02 to 0.40)    0.002   0.11 (0.02 to 0.53)   0.006
  Female vs male                                                          35/61 (57.4%)   35/66 (53.0%)   1.02 (0.37 to 2.78)    0.968                         
  Gestational age (weeks)                                                 38.8 (2.7)      39.3 (2.2)      0.78 (0.65 to 0.93)    0.006   0.79 (0.64 to 0.98)   0.030
  Mother LABA during pregnancy                                            12/61 (19.7%)   28/66 (42.4%    0.81 (0.27 to 2.46)    0.714                         
  Mother exacerbated during pregnancy                                     30/61 (49.2%)   19/66 (28.8%)   5.27 (1.74 to 15.93)   0.003   3.38 (1.02, 11.25)    0.047
  Mother caesarean section                                                19/58 (32.8%)   18/63 (28.6%)   1.55 (0.55 to 4.37)    0.409                         

\*Variables p\<0.10 included in multivariate regression with stepwise removal for best fit.

†Mean (SD).

FeNO, fractional exhaled nitric oxide; LABA, long-acting β-agonist.

Results {#s2}
=======

One hundred forty six infants (82%) completed follow-up at 12 months of age. There was no difference in prevalence of 'wheeze ever' between the FeNO and the clinical infant group (55.9 vs 52.4%). There was also no difference in wheezing and coughing frequency, triggers and severity between groups as evaluated by the specific domains of the standardised questionnaire.[@R4] However less infants born to mothers from the FeNO versus clinical group had recurrent episodes of bronchiolitis in the first year of life ([table 1](#THORAXJNL2013203388TB1){ref-type="table"}). There was also a statistical trend towards less croup episodes ([table 1](#THORAXJNL2013203388TB1){ref-type="table"}). As expected, greater gestational age was protective against recurrent bronchiolitis ([table 1](#THORAXJNL2013203388TB1){ref-type="table"}). The agreement between questionnaire data and standardised interview was 97% (0.89, p\<0.0001) for bronchiolitis. Maternal smoking and number of siblings did not significantly affect the relative risk for recurrent episodes of bronchiolitis (data not shown).

Comment {#s3}
=======

Asthma during pregnancy is associated with both premature birth and low birthweight,[@R5] which are risk factors for bronchiolitis. However, this did not explain our results because there was no difference in gestational age ([table 1](#THORAXJNL2013203388TB1){ref-type="table"}) and other pregnancy outcomes between the groups with the exception of reduced neonatal hospitalisation in the FeNO group.[@R3] The study design makes a reporting or recall bias as well as seasonal effects very unlikely as an alternative explanation for the observed effects even though symptoms and infections were reported retrospectively. We consequently have no data on disease severity, viral aetiology and time of infection in infancy, which are limitations of this study. Asthma exacerbations during pregnancy result in changes at the feto-maternal interface that favour aberrant immune responses in the foetus.[@R5] Mechanistically, immune and lung function, epigenetic and microbiome studies conducted in this birth cohort in the future all appear of interest. Together, our study identifies asthma in pregnancy as a potentially modifiable determinant in the prenatal origins of bronchiolitis with the prospect to be evaluated as a potential primary preventative strategy that could modulate the risk of childhood asthma.
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